The test sample ofloxacin powder was purchased from Sigma Aldrich, USA, and the remaining chemicals used during the experiments were purchased in India.

The test sample ofloxacin powder was divided into two parts and categorised as the control and Biofield Energy Treated ofloxacin. The control ofloxacin did not receive the Biofield Energy Treatment but treated by a “sham” healer who did not have any knowledge about the Biofield Energy Treatment. However, the Biofield Energy Treated ofloxacin was received the Consciousness Energy Healing Treatment remotely under standard laboratory conditions for 3 minutes by the renowned Biofield Energy Healer, Dahryn Trivedi, USA. The Biofield Energy Treatment was provided through the healer’s unique energy transmission process. After the treatment, both the ofloxacin samples were kept in sealed conditions and analyzed using LC-MS and GC-MS analytical techniques.

The LC chromatograms of both the ofloxacin samples showed the single major chromatographic peak at the retention time (Rt) 3.05 minutes (Figure 1). This Rt indicated that the polarity of both the control and Biofield Energy Treated ofloxacin remained the same. The peak area of the control sample was more than the treated ofloxacin. This indicated that the Biofield Energy Treated ofloxacin would be more stable compared to the control sample. This was proved by the study of the physicochemical properties of Biofield Energy Treated ofloxacin compared to the control sample 7.

Ofloxacin was detected with the molecular mass peak (M+H)+ at m/z 362 in the LC-MS spectrum in positive ion mode peak as per the literature 31. The mass spectra of both the samples of ofloxacin (Figure 2) at the retention time 3.05 minutes exhibited the mass of the protonated molecular ion peak at m/z 362.17 (M+H)+ (calculated for C18H21FN3O4+, 362.15), along with the fragment ion peaks near m/z 318.17, 261.08, and 213.92 corresponded to the molecular formula C17H21FN3O2+, C13H9FNO4+, and C9H5NO2+, respectively (Figure 3).

The LC-ESI-MS spectra of both the control and Biofield Energy Treated ofloxacin showed the mass of the molecular ion peak (M+H)+ at m/z 362.17 (calculated for C18H21FN3O4+, 362.15) with relative intensity of 100%. The theoretical calculation of PM+1 for ofloxacin was presented as below:

P (13C) = ^{(18 x 1.1%) x 100% (the actual size of the M+ peak)} / 100% = 18.8%

P (2H) = ^{(21 x 0.015%) x 100%} / 100%= 0.315%

P (15N) = ^{(3 x 0.4%) x 100%} / 100% = 1.2%

P (17O) = ^{(4 x 0.04%) x 100%} / 100% = 0.16%

PM+1, i.e. 2H, 15N, 13C, and 17O contributions from (C18H21FN3O4)+ to m/z 363.17 = 20.28%

From the above calculation, it has been found that 13C and 15N have major contribution to m/z 363.17. The calculated isotopic abundance is close to the experimental observed value (Table 1).

The LC-MS based isotopic abundance ratio of ofloxacin in control and Biofield Energy Treated ofloxacin samples were calculated for its molecular mass at m/z 362.17. The PM and PM+1 for ofloxacin were near m/z 362.17 and 363.17, respectively for both the samples, which were obtained from the observed relative peak intensities of (M+)and ((M+1)+)peaks, respectively (Table 1). The isotopic abundance ratio of PM+1/PM in the Biofield Energy Treated ofloxacin was significantly increased by 56.57% compared with the control sample (Table 1). Hence, 13C, 2H, 15N, and 17O contributions from (C18H21FN3O4)+ to m/z 363.17 in the treated ofloxacin were significantly increased compared with the control sample.

The retention time of the Biofield Energy Treated ofloxacin (23.31 minute) was close to those of the control sample (22.99 minutes). The peak area% of treated ofloxacin (85.45%) was almost closer compared to the control sample (86.54%). The molecular fragment peak at m/z 317 (calculated for C17H21FN3O2+, 317.15) and m/z 261 (calculated for C12H10N2O22+, 261.04) was observed in control and Biofield Energy Treated ofloxacin (Figure 4 and Figure 5) was proposed from both the mass spectra.

The mass peak intensities influence the isotopic abundance ratio, which was well supported by the LC-MS based isotopic abundance ratio analysis. The GC-MS spectra of both the control and Biofield Energy Treated ofloxacin showed the mass of the fragmented molecular ion peak ^M+ at m/z 317 (calculated for C17H21FN3O2+, 317.15). The theoretical calculation of PM+1 for ofloxacin was presented as below:

P (13C) = ^{(17 x 1.1%) x 36.13% (the actual size of the M+ peak)} / 100% = 6.76%

P (2H) = ^{(21 x 0.015%) x 36.13%} / 100%= 0.11%

P (15N) = ^{(3 x 0.4%) x 36.13%} / 100% = 0.43%

P (17O) = ^{(2 x 0.04%) x 36.13%} / 100% = 0.03%

PM+1, i.e. 2H, 15N, 13C, and 17O contributions from (C17H21FN3O2)+ to m/z 318 = 7.33%

From the above calculation, it has been found that 13C and 15N have a major contribution towards the m/z 318.

Similarly, the theoretical calculation of PM+2 for ofloxacin was presented as below:

P (18O) = ((2 x 0.20%) x 36.13%) / 100% = 0.14%

PM+2, i.e. 18O contributions from (C18H21FN3O4)+ to m/z 319 = 0.14%

From the above calculation, it has been found that 18O have major contribution to m/z 319. The calculated isotopic abundance is close to the experimental observed value (Table 2).

The GC-MS based isotopic abundance ratio analysis of ofloxacin in the control and treated ofloxacin samples were calculated for its fragmented molecular mass at m/z 317 (calculated for C17H21FN3O2+, 317.15). The PM, PM+1, and PM+2 for ofloxacin near m/z 317 ^M+, 318 ((M+1)+), and 319 ((M+2)+), respectively of both the samples in the ESI-MS spectra (Table 2). The isotopic abundance ratio of PM+1/PM in the treated ofloxacin was significantly increased by 9.53% compared with the control sample (Table 2). This indicated that the 13C, 2H, 15N, and 17O contributions from (C18H21FN3O4)+ to m/z 318 in the treated ofloxacin were significantly increased compared with the control sample. Similarly, the isotopic abundance ratio of PM+2/PM in the treated ofloxacin was increased by 12.94% compared with the control sample (Table 2). Hence, 18O contributions from (C18H21FN3O4)+ to m/z 319 in the treated ofloxacin were significantly increased compared with the control sample.

The LC-MS and GC-MS based isotopic abundance ratios of PM+1/PM (2H/1H or 15N/14N or 13C/12C or 17O/16O) and PM+2/PM (18O/16O) in the treated ofloxacin were significantly altered compared to the control sample. Modern physics explains that neutrinos change identities. It is only possible if the neutrinos possess mass and have the ability to interchange from one phase to another internally. The neutrinos have the ability to interact with protons and neutrons in the nucleus, which indicated a close relation between neutrino and the isotope formation 102829. The alteration in the isotopic composition in the Consciousness Energy Healing Treated ofloxacin might be the cause of the alteration in neutron to proton ratio in the nucleus. The improvement in isotopic abundance could be due to changes in nuclei possibly through the interference of neutrino particles via the Trivedi Effect® . The increased isotopic abundance ratio of the Consciousness Energy Healing Treated ofloxacin would increase the chemical bond strength and increase the stability in the body.

The new form of Biofield Energy Treated ofloxacin would be more stable compared to the control sample 32. It would be very useful to design better pharmaceutical formulations that might offer better therapeutic response against infections of the urethra, urinary tract infections, gonorrhea, infectious diarrhoea, pneumonia, chronic bronchitis, cellulitis, bacterial infection of the eye and ear, multidrug-resistant tuberculosis, prostatitis, plague, otitis media, etc.